Today’s value-based reimbursement programs require hospitals and health systems to shorten the length of time patients are hospitalized, reduce readmissions and improve quality of care. When post-acute infusion therapy is required, these challenges can be heightened, but are readily achievable for individuals who are relatively healthy, stable and financially secure. However, the risk of poor outcomes increases significantly for those who: are sicker and have comorbidities; have limited caregiver support; lack transportation options; or have Medicare without a Medigap plan, a high-deductible commercial plan or are uninsured or underinsured.
Ensuring all patients can be successfully transitioned to post-acute care as soon as possible requires a forward-thinking infusion provider that can offer comprehensive solutions for all patient types. Option Care’s highly trained and experienced multi-disciplinary teams of Clinical Care Transition Specialists, infusion nurses, pharmacists, dietitians, patient registration and reimbursement professionals ensure any patient that is able to go home, can go home by offering the following support:
For example, Option Care worked with the family of one patient who needed therapy for complex medical issues, but ran out of hospital days covered by his insurance plan and couldn’t afford the copay for post-acute care. Rather than face thousands of dollars in out-of-pocket costs, Option Care helped arrange financial assistance allowing him to be discharged from the hospital and get his medicine at home.
Option Care also supports hospitals and health systems as a valued post-acute infusion partner with extensive payer coverage, demonstrated quality results and access to a wide range of limited distribution specialty infusion drugs that can be delivered in a more affordable setting.
Many patients require infusion treatment upon discharge from the hospital. Partnering with a quality infusion provider ensures effective care transitions for all individuals, mitigating the risk for hospitals and health systems and ensuring patients have access to the treatment they need.
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
Opzelura May Reduce Need for Other Treatments in Atopic Dermatitis | AAD 2025
March 11th 2025Patients with atopic dermatitis who had not received biologics prior to treatment with Opzelura were able to avoid biologics during the 12 months after treatment with the topical nonsteroidal, finds study at American Academy of Dermatology Association annual meeting.
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
Supporting Patients with Type 1 Diabetes Through Education, Technology and Transparency
March 10th 2025Arti Masturzo, M.D., chief medical officer of CCS, spoke with MHE in this third part of a video series to share how CCS helps patients with type 1 diabetes effectively use glucose monitors and insulin pumps by providing clear guidance and troubleshooting support, recognizing that even minor errors in management can have significant health consequences.
Read More
Melanoma Treatment Advances Now Crossing into Other Skin Cancers
March 10th 2025Deborah S. Sarnoff, M.D., talks about the recent breakthrough treatments that are paving the way to treat patients with advanced basal cell carcinoma, squamous cell carcinoma and Merkel cell carcinoma, which is a rare and aggressive type of skin cancer.
Read More